1. Home
  2. BRO vs UTHR Comparison

BRO vs UTHR Comparison

Compare BRO & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brown & Brown Inc.

BRO

Brown & Brown Inc.

SELL

Current Price

$73.34

Market Cap

21.9B

Sector

Finance

ML Signal

SELL

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

SELL

Current Price

$579.26

Market Cap

23.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
BRO
UTHR
Founded
1939
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.9B
23.9B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
BRO
UTHR
Price
$73.34
$579.26
Analyst Decision
Hold
Buy
Analyst Count
21
15
Target Price
$75.22
★ $687.14
AVG Volume (30 Days)
★ 2.5M
449.2K
Earning Date
10-26-2026
11-04-2026
Dividend Yield
★ 0.98%
N/A
EPS Growth
N/A
★ 13.07
EPS
2.57
★ 18.80
Revenue
★ $5,902,000,000.00
$1,483,300,000.00
Revenue This Year
$19.76
$2.40
Revenue Next Year
$3.56
$10.58
P/E Ratio
★ $28.61
$31.27
Revenue Growth
★ 22.83
2.38
52 Week Low
$53.81
$455.63
52 Week High
$82.58
$614.23

Technical Indicators

Market Signals
Indicator
BRO
UTHR
Relative Strength Index (RSI) 59.34 51.92
Support Level $69.35 $559.33
Resistance Level $74.86 $586.61
Average True Range (ATR) 2.03 18.22
MACD 0.00 -2.96
Stochastic Oscillator 72.30 38.19

Price Performance

Historical Comparison
BRO
UTHR

About BRO Brown & Brown Inc.

Brown & Brown Inc is a diversified insurance agency, wholesale brokerage, insurance programs, and service. The company's business is divided into two reportable segments: (i) the Retail segment, and (ii) the Specialty Distribution segment. The Retail segment provides a broad range of insurance products and services to commercial, public and quasi-public entities, and to professional and individual customers, as well as non-insurance warranty services and products through automobile and recreational vehicle dealer services businesses. The Specialty Distribution segment consists of wholesale brokerage and specialty businesses. Its geographic area is U.S, U.K and Others.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: